All Outputs (8)

Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition (2018)
Journal Article
Chen, X., Low, K. H., Alexander, A., Jiang, Y., Karakas, C., Hess, K. R., …Keyomarsi, K. (2018). Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.ccr-18-1446

Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and phosphorylated-CDK2 are correlated with poor survival in TNBC patients,... Read More about Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.

Endocrine therapy for breast cancer: a model of hormonal manipulation (2018)
Journal Article
Johnston, S. J., & Cheung, K. (in press). Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncology and Therapy, https://doi.org/10.1007/s40487-018-0062-x

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited... Read More about Endocrine therapy for breast cancer: a model of hormonal manipulation.

Baseline quality of life evaluation in older women with primary operable breast cancer and its relationship with different treatments (2018)
Journal Article
Zahit, R. A., Parks, R. M., Howard, P., Blake, H., & Cheung, K. (2018). Baseline quality of life evaluation in older women with primary operable breast cancer and its relationship with different treatments. Journal of Clinical Oncology, 36(15/Sup), Article e12601. https://doi.org/10.1200/JCO.2018.36.15_suppl.e12601

Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort (2018)
Journal Article
Schuil, H., Derks, M., Liefers, G., Portielje, J., van de Velde, C., Syed, B., …Bastiaannet, E. (in press). Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort. Journal of Geriatric Oncology, https://doi.org/10.1016/j.jgo.2018.05.004

Objective: Clinical trials investigating breast cancer treatment often exclude or misrepresent older adults. This study compares treatment patterns and survival of older women diagnosed with breast cancer between a Dutch and a British observational c... Read More about Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort.

Fulvestrant for the treatment of advanced breast cancer (2018)
Journal Article
Blackburn, S. A., Parks, R. M., & Cheung, K. (2018). Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18(7), 619-628. https://doi.org/10.1080/14737140.2018.1473038

Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degr... Read More about Fulvestrant for the treatment of advanced breast cancer.

Optimising endocrine therapy in postmenopausal women with advanced breast cancer (2018)
Journal Article
Yau, T. H. L., & Cheung, K. (2018). Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer, 25(7), 705-721. https://doi.org/10.1530/ERC-18-0021

Hormone receptor-positive breast cancer is commonly treated with endocrine therapy; however, overtime cancer cells can develop endocrine resistance. This review aims to document combination therapy and sequential therapy in the use of endocrine agent... Read More about Optimising endocrine therapy in postmenopausal women with advanced breast cancer.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer (2018)
Journal Article
Robertson, J. F., Cheung, K., Noguchi, S., Shao, Z., Degboe, A., Lichfield, J., …Ellis, M. J. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 94, https://doi.org/10.1016/j.ejca.2018.02.026

Background The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) local... Read More about Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer (2018)
Journal Article
Gong, C., Man, E. P., Tsoi, H., Lee, T. K., Paul, L., Mak, S., …Khoo, U. (2018). BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer. Clinical Cancer Research, 24(15), 3681-3691. https://doi.org/10.1158/1078-0432.CCR-17-2259

Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resista... Read More about BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer.